 | Up a level |
Journal Article
Eberhardt, W. E. E., Rebmann, V., Rizvi, N., Antonia, S. J., Planchard, D., Cappuzzo, F., Mazieres, J., Zalcman, G., Lena, H., Wolf, J., Horn, L., Stinchcombe, T., Dy, G., Blackwood-Chirchir, A., Jin, C., Geese, W. J. and Ramalingam, S. S. (2017). First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO): checkMate 063. Oncol. Res. Treat., 40. S. 218 - 220. BASEL: KARGER. ISSN 2296-5262
Johnson, M. L., de langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y. and Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann. Oncol., 33 (7). S. S1417 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Lena, H., Rizvi, N. A., Wolf, J., Cappuzzo, F., Zalcman, G., Baas, P., Mazieres, J., Farsaci, B., Blackwood-Chirchir, M. A. and Ramalingam, S. (2016). Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses. J. Thorac. Oncol., 11 (4). S. S115 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Ramalingam, S. S., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B. J. and Rizvi, N. A. (2014). Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys., 90 (5). S. 1266 - 1268. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X